# A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

> **NCT03207425** · PHASE1 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 29 (actual)

## Conditions studied

- NASH

## Interventions

- **DRUG:** EDP 305

## Key facts

- **NCT ID:** NCT03207425
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-14
- **Primary completion:** 2017-09-16
- **Final completion:** 2017-09-19
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207425, "A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03207425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*